Evaluation Of Efficacy Of Liquid Platelet Rich Fibrin In Temporomandibular Joint Disorders
Temporomandibular Joint Disorders
About this trial
This is an interventional treatment trial for Temporomandibular Joint Disorders focused on measuring Liquid Platelet Rich Fibrin, Temporomandibular Joint Disorders, Wilkes classification
Eligibility Criteria
Inclusion Criteria:
- Unilateral internal temporomandibular disorder
- localized temporomandibular joint pain
- Scoring 3 and above in Wilke's classification.
Exclusion Criteria:
- Autoimmune diseases
- Significant mechanical obstruction that prevents mouth opening
- Acute capsulitis,
- Benign or malignant temporomandibular joint lesions
- Neurological disorders,
- Blood diseases and coagulation disorders
- Patients with a history of allergies or anaphylactic shock.
Sites / Locations
- Aydın Adnan Menderes University, Faculty of Dentistry, Department of Oral and Maxillofacial SurgeryRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Arthrocentesis
Arthrocentesis plus i-PRF injection
2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. Only the second needle was removed without removing the first needle inserted. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.